Myelodysplastic syndrome with excess blasts-2
MONDO:0015041A myelodysplastic syndrome defined by 10-19% blasts in the bone marrow or 5-19% blasts in the blood and <10% blasts in the bone marrow. Approximately 33% of cases progress to acute leukemia. The prognosis is usually poor. (WHO)
Also known as: MDS-EB-2, RAEB-2, RAEB-II, myelodysplastic syndrome with Excess blasts-2, refractory anaemia with excess blasts type 2, refractory anemia with excess blasts type 2
1861 clinical trials for this condition and its sub-types, 12 tagged with Myelodysplastic syndrome with excess blasts-2 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Hope for kids with leukemia: new drug combo aims to boost remission
Disease control Recruiting nowThis phase 2 trial tests whether adding the targeted drug venetoclax to standard chemotherapy is safe and effective for children and young adults (up to age 22) with newly diagnosed acute myeloid leukemia (AML). The study aims to see if this combination can reduce the amount of c…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Could a targeted pill boost chemo for tough blood cancer?
Disease control Recruiting nowThis Phase 3 trial tests whether adding the drug venetoclax to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia (AML) or a related high-risk condition. About 650 participants aged 18 to 75 will receive either venetoclax or a placebo alongside chemo. …
Phase 3 • Sponsor: University of Ulm • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug HC-7366 tested for tough leukemia
Disease control Recruiting nowThis early-phase trial is testing a new drug called HC-7366 in 18 adults with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The main goal is to find a safe dose and check for side effects. Researchers hope this drug may offer a new option f…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Promising new combo aims to wipe out leukemia cells more effectively
Disease control Recruiting nowThis phase 2 trial is testing whether adding the targeted drug venetoclax to a standard chemotherapy regimen (FLAG IDA) works better than the usual treatment for adults newly diagnosed with acute myeloid leukemia (AML). About 102 participants will receive either the new combinati…
Phase 2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Donor immune cells join fight against Hard-to-Treat leukemia
Disease control Recruiting nowThis early-phase trial tests whether adding natural killer (NK) cells from a healthy donor to the standard drugs azacitidine and venetoclax can help control acute myeloid leukemia (AML). About 32 adults with relapsed or hard-to-treat AML will receive the combination. The main goa…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental drug combo offers hope for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial is testing a chemotherapy drug called CPX-351 in people with high-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) that came back or didn't respond to standard treatment. The goal is to find the best dose that is safe and to se…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC